eFFECTOR Therapeutics Reports Data Updates From Phase 2 Expansion Cohorts Evaluating Zotatifin In Patients With ER+ Metastatic Breast Cancer At ASCO 2023 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
eFFECTOR Therapeutics reported data updates from Phase 2 expansion cohorts evaluating Zotatifin in ER+ metastatic breast cancer patients at ASCO 2023. Partial responses were observed in 26% of evaluable patients treated with Zotatifin combined with fulvestrant and abemaciclib. The combinations were generally well tolerated.
May 25, 2023 | 8:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
eFFECTOR Therapeutics reported positive Phase 2 data for Zotatifin in ER+ metastatic breast cancer patients, with 26% partial responses observed.
The positive Phase 2 data for Zotatifin in ER+ metastatic breast cancer patients indicates potential for the drug's success in further trials and eventual market approval. This could lead to increased investor interest and a positive short-term impact on EFTR's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100